Search Tag: antiplatelet therapy

ICU Management

Isicem22-the-place-of-antiplatelet-agents-in-covid-19-remap-cap-trial

2022 22 Mar

Thrombotic events are common in patients hospitalised with COVID-19. Platelet activation has been implicated in the COVID-19 inflammatory response. However, the efficacy of antiplatelet therapy in critically ill patients with COVID-19 is still uncertain.  The Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia...Read more

Cardiology Management

Dual-antiplatelet-therapy-does-not-reduce-risk-of-adverse-events

2015 17 Mar

According to a study published in JAMA, an additional 18 months of dual antiplatelet therapy (DAPT) after coronary stent replacement did not result in any significant differences in rates of stent thrombosis, adverse cardiac and cerebrovascular events or bleeding, compared to placebo. Current guidelines recommended a minimum of 1 month of DAPT after...Read more

Pharmacy Management

Aspirin-may-protect-against-liver-fibrosis

2014 12 Nov

According to new research, aspirin is effective against liver fibrosis, especially in people who are at risk for chronic liver disease. The drug is already well-known for its cardiovascular and anti-inflammatory benefits. Gordon Jiang, MD, a gastroenterology fellow at the Beth Israel Deaconess Medical Center in Boston, revealed this latest development...Read more

ICU Management

Study-renal-denervation-fails-to-lower-bp

2014 04 Apr

A recent study, presented at the meeting of the American College of Cardiology (ACC) in Washington and published by the New England Journal of Medicine, has cast a doubt over therapy used in more than 80 countries and prescribed to treat hypertension that does not respond to drugs. Renal artery denervation is an intervention in which nerve connections...Read more

Cardiology Management

Outcome-of-dual-antiplatelet-therapy-following-drug-releasing-stent-implant-not-tied-to-duration

2013 01 Nov

A new study evaluating the effects of short-term (defined as three months) versus long-term (one year) dual anti­platelet therapy shows that the shorter duration treatment does not result in poorer outcomes on certain measures such as death, heart attack, stroke, and bleeding for patients with coronary artery disease or low-risk acute coronary syndromes...Read more